IL33 and neoplasm: This tumor-derived IL33 binds to ST2 receptors on mast cells, which become activated and release macrophage-attracting factors Csf2, Ccl3, and Il6. Infiltrating macrophages then coordinate their well-known pro-tumor effects, such as increased angiogenic Vegfa expression (Eissmann et al., 2019).